[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549370":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":16,"locations":7,"responsibleParty":25,"collaborators":7,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":7,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":35,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":36,"phases":7,"briefSummary":33,"conditions":37,"keywords":39,"overallStatus":46,"whyStopped":7,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":51,"locationsCount":7},{"fullName":5,"class":6},"Basilea Pharmaceutica","INDUSTRY",null,[9,13],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Fosmanogepix solution for infusion","Fosmanogepix solution for infusion, 20 mg\u002FmL for intravenous administration",{"type":10,"name":14,"description":15,"armGroupLabels":7,"otherNames":7},"Fosmanogepix 400 mg tablets","Fosmanogepix 400 mg tablets for oral administration",[17,21],{"name":18,"role":19,"phone":7,"phoneExt":7,"email":20},"WEP-Clinical Pharmaceutical Services Provider","CONTACT","fosmanogepixeap@wepclinical.com",{"name":22,"role":19,"phone":23,"phoneExt":7,"email":24},"Marc Engelhardt","+41 79 701 0551","marc.engelhardt@basilea.com",{"type":26,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100549370","expanded-access-to-fosmanogepix-for-patients-with-serious-or-life-threatening-invasive-fungal-infections-100549370",false,"NCT06433128","Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections","Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections Who Have no Other Treatment Options","The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.","ALL","12 Years","EXPANDED_ACCESS",[38],"Invasive Fungal Infections",[40,41,42,43,44,45],"Fungal infection","Candida","Anti-fungal","Yeast","Mold","Rare mold","AVAILABLE","2025-07-23",{"date":49,"type":50},"2025-07-24","ACTUAL",{"name":5,"class":6}]